while CPAP developer ResMed also increased its rank. Click through the listings below to learn more about the companies powering the global medical device industry, and read more about the 2024 ...

Many analysts see GLP-1 drugs, which have shown positive results in treating sleep apnea, as a threat to CPAP companies. But ResMed, which makes sleep apnea devices, sees an opportunity.

NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post ...

Learn More ResMed (ASX: RMD) shares are outperforming the market on Tuesday. In afternoon trade, the sleep disorder treatment company's shares are up 2% to $35.73. This compares favourably to a 0. ...

ResMed’s CPAP (continuous positive airway pressure) product, the AirFit N20. The California-based company, founded by Mr Farrell’s father in Sydney 35 years ago, is also listed on the ASX.

such as the AirTouch N30i next-generation CPAP mask unveiled earlier today. Capitalize on ResMed’s market opportunity and brand advantage in broader sleep health and breathing health adjacencies ...

With interactive coaching and nightly sleep data tracking, MyAir helps increase CPAP usage, with 87% of patients achieving therapy compliance. (ResMed also launched a new CPAP mask today — read ...

[Image courtesy of ResMed] ResMed (NYSE: RMD) + announced today that it launched its new AirTouch N30i continuous positive airway pressure (CPAP) mask. ResMed says it developed the AirTouch N30i ...

PERRY, Florida — The U.S. Southeast grappled Sunday with rising death tolls, a lack of vital supplies in isolated, flood-stricken areas and the widespread loss of homes and property while the ...

Flying with a CPAP machine resulted in many headaches for one journalist traveling this past summer between New York and Reykjavik on Icelandair. (Photo by Nicolas Economou/NurPhoto via Getty ...